CSV April 28, 2023 through April 28, 2025 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
GLYCERYL TRI	ASSAY/*Content*	*First*	Online	28-Sep-2018	1-Oct-2018	*USP43–NF38*	*Second*	This erratum

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CAPRYLATE	*of Triglycerides*	*Supplement to USP41–NF36*					*Supplement to USP41–NF36*	applies to the new *USP-NF* ONLINE platform only. Line 1 of *System suitability solution*: Change 20 mUSP Glyceryl Monocaprylate RSUSP Glyceryl Monocaprylate RSg/mL each of 1-monooctanoyl-rac-glycerol and 1-monodecanoyl-rac-glycerol in tetrahydrofuran to: 20 mg/mL each of 1-monooctanoyl-rac-glycerol and 1-monodecanoyl-rac-glycerol in tetrahydrofuran
METHADONE HYDROCHLOR	ASSAY/ *Procedure*	*USP41–NF36*	2628	28-Sep-2018	1-Oct-2018	*USP43–NF38*	*Second Supplement to*	In the *Analysis*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
IDE INJECTION							*USP41–NF36*	Result = $(R_U/R_S) \times W \times 100$ to: Result = $(R_U/R_S) \times W$
NIFEDIPINE EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/Test 5*	*First Supplement to USP41–NF36*	8369	28-Sep-2018	1-Oct-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Line 1 of *Standard stock solution*: Change 50 mg of USP Nifedipine RS in *Diluent A* and water (50:50) to: 0.50 mg/mL of USP Nifedipine RS prepared as follows. Transfer a suitable amount of USP Nifedipine RS to an appropriate volumetric flask. Dissolve in 50% of the flask volume of *Diluent A*. Dilute with water to volume.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								AND Line 1 of *Instrumental condit ions/Analytical wavelength*: Change 238 nm to: 338 nm
PRAVASTATIN SODIUM	ADDITIONAL R EQUIREMENT S	*First Supplement to USP41–NF36*	Online	28-Sep-2018	1-Oct-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	This erratum applies to the new *USP-NF* ONLINE platform only. Line 2 of *USP Reference Standards <11>*: Change USP Pravastatin Related Compound A RS to: USP Pravastatin 1,1, 3,3-Tetramethyl butylamine RS
TRIAMTERENE	ADDITIONAL R EQUIREMENT	*First Supplement to*	Online	28-Sep-2018	1-Oct-2018	*USP43–NF38*	*Second Supplement to*	This erratum applies to the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	S	*USP41–NF36*					*USP41–NF36*	new *USP-NF* ONLINE platform only. Line 4 of *USP Reference Standards* <*11*>: Change USP Doxazosin Related Compound A RS to: USP Triamterene Related Compound A RS
ORDINARY IMPURITIES	KEY FOR VISUALIZATION TECHNIQUES	*USP41–NF36*	Online	28-Sep-2018	1-Oct-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	This erratum applies to the new *USP-NF* ONLINE platform only. Change 3. *Solution A*–Mix 850 mg of bismuth subnitrate with 40 mL of water and 10 mL of glacial acetic acid.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								4. *Solution B*–Dissolve 8 g of potassium iodide in 20 mL of water. Mix A and B together to obtain a Stock Solution which can be stored for several months in a dark bottle. Mix 10 mL of the Stock Solution with 20 mL of glacial acetic acid, and dilute with water to make 100 mL, to prepare the spray reagent. to: 3. *Solution A*–Mix 850 mg of bismuth subnitrate with 40 mL of water and 10 mL of glacial acetic acid.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Solution B–Dissolve 8 g of potassium iodide in 20 mL of water. Mix A and B together to obtain a Stock Solution which can be stored for several months in a dark bottle. Mix 10 mL of the Stock Solution with 20 mL of glacial acetic acid, and dilute with water to make 100 mL, to prepare the spray reagent. AND Update list numbers 5–23 to: 4–22
LOXAPINE SUCCINATE	IM PURITIES/*Organic*	*USP41–NF36*	2486	28-Sep-2018	1-Oct-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	In the variable definition list in *Analysis*: Add

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Impurities/Procedure							F = relative response factor (see *Impurity Table 1*)
INSULIN ASSAYS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP41–NF36*	6054	28-Sep-2018	1-Oct-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	This erratum applies to the new *USP-NF* ONLINE platform only. Delete USP Insulin RS
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE OPHTHALMIC SOLUTION	IMPURITIES/*Organic Impurities: Dorzolamide Hydrochloride*	*First Supplement to USP41–NF36*	Online	28-Sep-2018	1-Oct-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	This erratum applies to the new *USP-NF* ONLINE platform only. In the first variable definition list in *Analysis*: Change C_S = concentration of USP Doxazosin Related Compound D RS in the *Standard solution* (mg/mL) to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								C_S = concentration of USP Dorzolamide Related Compound D RS in the *Standard solution* (mg/mL) AND In the second variable definition list in *Analysis*: Change C_S = concentration of USP Doxazosin Related Compound B RS in the *Standard solution* (mg/mL) to: C_S = concentration of USP Dorzolamide Related

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TRANYLCYPROMINE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*First Supplement to USP41–NF36*	Online	28-Sep-2018	1-Oct-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Compound B RS in the *Standard solution* (mg/mL) This erratum applies to the new *USP-NF* ONLINE platform only. Change *System suitability* ? ?1S *(USP41)* *Sample*: *Standard solution* *Suitability requirements* *Tailing factor*: NMT 2.0 to: *System suitability* *Sample*: *Standard solution* *Suitability requirements* ? ?1S *(USP41)* *Tailing factor*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ISOLEUCINE	IM PUR ITIES/*Related Compounds*	*First Supplement to USP41–NF36*	Online	28-Sep-2018	1-Oct-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	NMT 2.0 This erratum applies to the new *USP-NF* ONLINE platform only. Line 1 of *Standard solution*: Change USP L-Leucine RS to: USP L-Isoleucine RS
CYCLOPHOSPHAMIDE	ASSAY/ *Procedure*	*USP41–NF36*	1123	28-Sep-2018	1-Oct-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	In the variable definition in *Analysis*: Change C_S = concentration of USP Cyclophosphamide RS in the *Standard solution* (mg/mL). [Note—Concentration is calculated on the anhydrous basis.] C

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								C_U = concentration of Cyclophosphamide in the *Sample solution* (mg/mL). [Note—Nominal concentration is calculated on the anhydrous basis.] to: C_S = concentration of USP Cyclophosphamide RS in the *Standard solution* (mg/mL) C_U = concentration of Cyclophosphamide in the *Sample solution* (mg/mL)
NAPROXEN TABLETS	IMPURITIES/*Organic Impurities*	*USP41–NF36*	2865	28-Sep-2018	1-Oct-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Line 3 of *System suitability solution*: Change 0.5 mg/mL of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								USP Naproxen RS and 0.5 µg/mL of USP Naproxen Related Compound A RS in *Diluent*, from *Standard stock solution 1* and *Standard stock solution 2*, respectively to: 0.5 µg/mL of USP Naproxen Related Compound A RS from *Standard stock solution 2* and 0.5 mg/mL of USP Naproxen RS in *Diluent*
VITAMIN D ASSAY	ASSAY/ *Procedure 8*	*First Supplement to USP41–NF36*	Online	28-Sep-2018	1-Oct-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Line 1 of *Aqueous potassium hydroxide solution*: Change 800 mg to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SUMATRIPTAN NASAL SPRAY	ASSAY/ *Procedure*	*First Supplement to USP41–NF36*	Online	28-Sep-2018	1-Oct-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	800 g This erratum applies to the new *USP-NF* ONLINE platform only. In the variable definition in *Analysis*: Change C_S = concentration of USP Sumatriptan Succinate Related Compound A RS to: C_S = concentration of USP Sumatriptan Succinate RS
TRANEXAMIC ACID INJECTION	SPECIFIC TESTS	*First Supplement to USP41–NF36*	Online	28-Sep-2018	1-Oct-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	This erratum applies to the new *USP-NF* ONLINE platform only. Change *Dissolution*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								<*711*>: Meets the requirements to: *Sterility Tests* <*71*>: Meets the requirements
ACETAMINOPHEN ORAL SUSPENSION	IMPURITIES/*Organic Impurities*	*Revision Bulletin (Official August 01, 2018)*	Online	28-Sep-2018	1-Oct-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	This erratum applies to the new *USP-NF* ONLINE platform only. Change *Solution B*: 0.2% trifluoroacetic acid in water to: *Solution B*: 0.2% trifluoroacetic acid in acetonitrile
ELASTOMERIC CLOSURES FOR INJECTIONS	PHYSICOCHEMICAL TESTS/*Heavy Metals*	*Revision Bulletin (Official January 01, 2018)*	Online	31-Aug-2018	1-Sep-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Change *Test preparation*: Into a 50-mL color-comparison tube place 10.0 mL of *Solution S*.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: *Test preparation*: Into a 50-mL color-comparison tube pipet 10.0 mL of *Solution S* and dilute with water to 25 mL. Using a pH meter or short-range pH indicator paper as external indicator, adjust with 1 N acetic acid or 6 N ammonium hydroxide to a pH of between 3.0 and 4.0, dilute with water to 40 mL, and mix.
AMIKACIN SULFATE INJECTION	ASSAY/ *Procedure*	*USP41–NF36*	203	31-Aug-2018	1-Sep-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Variable definition list in *Analysis*: Change C_U = nominal concentration of amikacin in the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Sample solution to: C_U = nominal concentration of amikacin in the *Sample solution* (mg/mL)
FISH OIL CONTAINING OMEGA-3 ACIDS CAPSULES	DEFINITION	*USP41–NF36*	4620	31-Aug-2018	1-Sep-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Line 6: Change Scombroidae, to: Scombridae,
INSULIN LISPRO INJECTION	PRODUCT-RELATED SUBSTANCES AND IM PUR ITIES/*Related Substances*	*USP41–NF36*	2180	31-Aug-2018	1-Sep-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Line 3 of *Analysis*: Change Calculate the percentage of insulin lispro, A-21 desamido insulin lispro, and other impurities in the portion of Insulin Lispro taken: to: Calculate the percentage of insulin lispro, A-21 desamido insulin lispro,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								and other impurities in the portion of Injection taken:
HAZARDOUS DRUGS - HANDLING IN HEALTHCARE SETTINGS	REFERENCES	*Revision Bulletin (Official December 01, 2017)*	Online	31-Aug-2018	1-Sep-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Reference 37: Delete http://www.osha.gov/Publications/osha3151.html.
AMINOBENZOATE POTASSIUM	IM PURITIES/*Limit of Aniline and p-Toluidine*	*USP41–NF36*	209	31-Aug-2018	1-Sep-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Line 3 of *System suitability*: Change [Note—The relative retention times of aniline and *p*-toluidine are about 4.1 and 5.1 min, respectively.] to: [Note—The relative retention times of aniline and *p*-toluidine are 0.8 and 1.0, respectively.]
FISH OIL	DEFINITION	*USP41–NF36*	4622	31-Aug-2018	1-Sep-2018	*USP43–NF38*	*Second*	Line 7: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CONTAINING OMEGA-3 ACIDS DELAYED-RELEASE CAPSULES							*Supplement to USP41–NF36*	Scombroidae, to: Scombridae,
MILRINONE LACTATE INJECTION	IMPURITIES/*Organic Impurities*	*USP41–NF36*	2748	31-Aug-2018	1-Sep-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Equation in *Analysis*: Change Result = $(r_U/r_S) \times (C_S/C_U) \times (Mr_1/Mr_2) \times 100$ to: Result = $(r_U/r_S) \times (C_S/C_U) \times 100$ AND In the variable definition list: Delete Mr_1 = molecular weight of milrinone free base, 211.22 Mr_2 = molecular weight of milrinone lactate, 151.16
HYDROCHLOROTHIAZIDE CAPSULES	PERFORMANCE TESTS/*Dissolution*/*Test 2*	*USP41–NF36*	2049	31-Aug-2018	1-Sep-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Line 1 of *Empty capsules solution*: Change Place 10

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ASSESSMENT OF EXTRACTABLES ASSOCIATED WITH PHARMACEUTICAL PACKAGING/DELIVERY SYSTEMS	REFERENCES	*USP41–NF36*	7910	27-Jul-2018	1-Aug-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Capsules into to: Place 10 empty capsules into Line 2 of reference 7: Delete http://webstore.ansi.org/RecordDetail.aspx?sku=ASTM%20F1980-07(2011)&source=msn&adgroup=astm. Accessed 19 March 2013.
FISH OIL CONTAINING OMEGA-3 ACIDS	DEFINITION	*USP41–NF36*	4617	27-Jul-2018	1-Aug-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Line 5: Change Scombroidae, to: Scombridae,
SODIUM FLUORIDE AND ACIDULATED PHOSPHATE TOPICAL SOLUTION	ASSAY	*First Supplement to USP41–NF36*	8423	27-Jul-2018	1-Aug-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Line 1 of *Sample solution*: Change 1.1 µg/mL of sodium fluoride to: 0.5 µg/mL of fluoride ion AND In the variable

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								definition list in *Analysis*: Change C_U = nominal concentration of sodium fluoride in the *Sample solution* (µg/mL) to: C_U = nominal concentration of fluoride ion in the *Sample solution* (µg/mL)
REAGENTS	CHROMATOGRAPHIC COLUMNS/*Packings*	*USP41–NF36*	5776	27-Jul-2018	1-Aug-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Line 2 of *L73*: Delete [Note—Available as Jordi-Gel DBV from www.jordiflp.com.]
DEXAMETHASONE SODIUM PHOSPHATE INJECTION	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP41–NF36*	1204	27-Jul-2018	1-Aug-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Delete USP Endotoxin RS
RACEPINEPHRINE INHALATION SOLUTION	ADDITIONAL REQUIREMENTS	*USP41–NF36*	3564	27-Jul-2018	1-Aug-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Add *USP Reference Standards <11>* USP Epinephrine

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
MICONAZOLE NITRATE	IM PUR ITIES/*Organic Impurities*	*First Supplement to USP41–NF36*	Online	27-Jul-2018	1-Aug-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Bitartrate RS (Note: This errata applies to the new *USP-NF* ONLINE platform only.) Line 1 of *Standard solution*: Change 1.2 µg/mL each of USP Miconazole Nitrate RS, USP Econazole Nitrate RS, USP Doxazosin Related Compound C RSUSP Doxazosin Related Compound C RS, USP Miconazole Related Compound F RS, and USP Miconazole Related Compound I RS

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								in *Diluent* to: 1.2 µg/mL each of USP Miconazole Nitrate RS, USP Econazole Nitrate RS, USP Miconazole Related Compound C RS, USP Miconazole Related Compound F RS, and USP Miconazole Related Compound I RS in *Diluent* AND In the first variable definition list in *Analysis*: Change C_S = concentration of USP Doxazosin Related Compound C

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								RS, USP Doxazosin Related Compound F RS, USP Miconazole Related Compound I RS, or USP Miconazole Nitrate RS in the *Standard solution* (µg/mL) to: C_S = concentration of USP Miconazole Related Compound C RS, USP Miconazole Related Compound F RS, USP Miconazole Related Compound I RS, or USP Econazole Nitrate RS in

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								the *Standard solution* (µg/mL)
GLUCAGON BIOIDENTITY TESTS	*B. In Vitro Cell-Based Bioidentity Test*	*First Supplement to USP41–NF36*	8627	27-Jul-2018	1-Aug-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Line 1 of *Medium B*: Change Kreb's salt solution containing 0.3% (v/v) human serum albumen to: Krebs' salt solution containing 0.3% (v/v) human serum albumin AND Line 1 of *Medium C*: change Kreb's salt solution containing 0.3% (v/v) human serum albumen to: Krebs' salt solution containing 0.3% (v/v) human serum albumin

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
FOLIC ACID INJECTION	*USP Reference standards <11>*	*USP41–NF36*	1866	27-Jul-2018	1-Aug-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Delete USP Endotoxin RS
ZIPRASIDONE HYDROCHLORIDE	IMPURITIES/*Organic Impurities*	*Second Supplement to USP41–NF36*	8992	27-Jul-2018	1-Aug-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	In the second variable definition in *Analysis*: Change r_U = peak response of chloroindolinone or ziprasidone related compound F from the *Sample solution* to: r_U = peak response of chloroindolinone, ziprasidone related compound F, or any unspecified impurity from the *Sample solution*
PLASTIC MATERIALS OF CONSTRUCTION	TEST METHODS	*USP41–NF36*	6403	27-Jul-2018	1-Aug-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Line 1 of *Plastic Additives/Reference solutio*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								ns/*Reference solution I*: Change 0.24 mg/mL of USP Plastic Additive 4 RS prepared in the *Solvent mixture* to: 0.24 mg/mL of USP Plastic Additive 4 RS prepared in methylene chloride AND Line 1 of *Reference solution J*: Change 0.24 mg/mL of USP Plastic Additive 5 RS prepared in the *Solvent mixture* to: 0.24 mg/mL of USP Plastic Additive 5 RS prepared in methylene

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								chloride AND Line 1 of *Poly(ethylene-vinyl acetate)/Polyvinyl chloride, plasticized/Reference solutions U, V, W*: Change 0.1-mg/mL solutions to: 10.0-mg/mL solutions
DIVALPROEX SODIUM DELAYED-RELEASE CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>/Test 2*	*USP41–NF36*	1354	27-Jul-2018	1-Aug-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Line 1 of *Tolerances*: Change NMT 20% (*Q*) of the labeled amount of to: NMT 20% of the labeled amount of
RACEPINEPHRINE HYDROCHLORIDE	*USP Reference standards <11>*	*USP41–NF36*	3565	27-Jul-2018	1-Aug-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Add USP Epinephrine Bitartrate RS
MICONAZOLE NITRATE	ADDITIONAL REQUIREMENT	*First Supplement to*	Online	27-Jul-2018	1-Aug-2018	*USP43–NF38*	*Second Supplement to*	(Note: This errata applies to

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	S	*USP41–NF36*					*USP41–NF36*	the new *USP-NF* ONLINE platform only.) Line 4 of *USP Reference Standards* <*11*>: Change USP Doxazosin Related Compound C RS to: USP Miconazole Related Compound C RS AND Line 7 of *USP Reference Standards* <*11*>: Change USP Econazole Nitrate RS to: USP Miconazole Related Compound F RS
REAGENTS	REAGENTS,	*USP41–NF36*	5737	27-Jul-2018	1-Aug-2018	*USP43–NF38*	*Second*	Line 4 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	INDICATORS, AND S OL UTION S/*Reagent Specifications*						*Supplement to USP41–NF36*	*N-(2-Tetrahydrofuroyl)piperazine*: Change EMS-DOTTIKON, www.ems-dottikon.ch. to: Oakwood Chemical, www.oakwoodchemical.com.
BUPROPION HYDROCHLORIDE	IDENTIFICATION/*C. Identification Tests—General <191>, Chloride*	*USP41–NF36*	573	27-Jul-2018	1-Aug-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Line 1 of *Acceptance criteria*: Change Meets the requirements of test to: Meets the requirements of test *A*
RACEPINEPHRINE	*USP Reference standards <11>*	*USP41–NF36*	3564	27-Jul-2018	1-Aug-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Add USP Epinephrine Bitartrate RS
MICONAZOLE NITRATE	ASSAY/*Procedure*	*First Supplement to USP41–NF36*	Online	27-Jul-2018	1-Aug-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	(Note: This errata applies to the new *USP-NF* ONLINE platform only.)

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Line 1 of *System suitability solution*: Change 0.1 mg/mL of USP Miconazole Nitrate RS and 6 µg/mL of USP Econazole Nitrate RS in *Diluent*. to: 0.1 mg/mL of USP Miconazole Nitrate RS and 6 µg/mL of USP Miconazole Related Compound F RS in *Diluent*.
POLYDEXTROSE	ASSAY/ *Procedure*	*First Supplement to USP41–NF36*	8491	29-Jun-2018	1-Jul-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 1 of *Sample solution*: Change Polydextrose, calculated on the anhydrous and ash-free

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								basis, in *Mobile phase* to: Polydextrose in *Mobile phase* AND Line 1 of *Acceptance criteria*: Change NLT 90.0% to: NLT 90.0% on the anhydrous and ash-free basis
HYDROGENAT ED POLYDEXT ROSE	ASSAY/ *Procedure*	*USP41–NF36*	5495	29-Jun-2018	1-Jul-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Change *Standard solution*: 4.0 mg/mL of USP Polydextrose RS, calculated on the anhydrous and ash-free basis, in *Mobile phase* *Sample solution*: 4.0 mg/mL of Hydrogenated Polydextrose, calculated on

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								the anhydrous and ash-free basis, in *Mobile phase* to: *Standard solution*: 4.0 mg/mL of USP Polydextrose RS in *Mobile phase* *Sample solution*: 4.0 mg/mL of Hydrogenated Polydextrose in *Mobile phase*
NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY IDENTITY TESTING OF BACTERIAL POLYSACCHARIDES USED IN VACCINE MANUFACTURE	2. PROCEDURE	*First Supplement to USP41–NF36*	8633	29-Jun-2018	1-Jul-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 3 of *2.1 Equipment R equirements/Processing Parameters*: Change adsorption to: absorption
CALCIUM CITRATE MALATE	IM PURITIES/*Limit of Fluoride*	*First Supplement to USP41–NF36*	8299	29-Jun-2018	1-Jul-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 1 of *Standard solution*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Change Transfer 1.0 mL of *Standard stock solution* to: Transfer 2.0 mL of *Standard stock solution*
CHORIONIC GONADOTROPIN FOR INJECTION	ADDITIONAL REQUIREMENTS	*USP41–NF36*	1982	29-Jun-2018	1-Jul-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 2 of *USP Reference Standards* <*11*>: Delete USP Endotoxin RS
ESZOPICLONE	ADDITIONAL REQUIREMENTS/*USP Reference Standards*	*Second Supplement to USP41–NF36*	Online	25-May-2018	1-Jun-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 2 of USP Eszopiclone Related Compound A RS: [Note—This material may be available in the free base or salt form.] 6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyrazin-5-yl 4

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-methylpiperazine-1-carboxylate 4-oxide. $C_{17}H_{17}ClN_6O_4$ 404.81 6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyrazin-5-yl 4-methylpiperazine-1-carboxylate 4-oxide, 3-chlorobenzoic salt (1:1). $C_{17}H_{17}ClN_6O_4 \cdot C_7H_5ClO$ 561.38 to: [Note—This material may be available in the free base or salt form.] 6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5*H*-pyrrolo[3,4

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-*b*]pyrazin-5-yl 4-methylpiperazine-1-carboxylate 4-oxide. $C_{17}H_{17}ClN_6O_4$ 404.81 6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyrazin-5-yl 4-methylpiperazine-1-carboxylate 4-oxide, 3-chlorobenzoate salt (1:1). $C_{17}H_{17}ClN_6O_4 \cdot C_7H_5ClO_2$ 561.38

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 15
- Page 16
- Page 17

- Page 18
- Page 19
- Page 20
- Page 21
- Page 22
- Page 23
- …
- Next page Next ›
- Last page Last »